Stock Analiz

Inogen Inc INGN

Industrial Specialties · IPO 2014 · data as of November 13, 2026

$5.69Market cap $148M
Open the interactive analysis →

Inogen Inc (INGN) is a healthcare company listed in the US with a market value of about $148M. In the twelve months to September 30, 2026 it had revenue of $379M and net income of -$35M, a net margin of -9.3%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (2/5); the weakest is track record (0/5).

Key numbers: 5-year revenue growth of 2% a year, a 5-year average ROIC of -19%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 38% above the current price.

About Inogen

Inogen is listed in the US and classified in industrial specialties, IPO year 2014. Revenue went from $203M in 2016 to $349M in 2025, growth of about 6.2% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 16% over three years (dilution for shareholders). It spends 6% of revenue on research and development.

Score: 1.2 / 5

Value1/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.4
P/B0.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-7.7%
Shareholder yield0.0%
Intrinsic value vs. price+38%

Growth and quality

Revenue growth (1 yr)3.9%
Revenue growth (5 yrs, per year)2.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-14.7%
ROIC (5-yr avg.)-18.6%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$379M$349M$336M$316M$377M$358M$308M$362M$358M$249M$203M
Net income-$35M-$23M-$36M-$102M-$84M-$6M-$6M$21M$52M$21M$21M
Free cash flow-$11M-$14M$3M-$8M-$41M$18M$33M$37M$52M$58M$29M
EPS (diluted)$-1.32$-0.86$-1.52$-4.42$-3.67$-0.28$-0.27$0.94$2.30$0.96$0.97
Net margin-9.3%-6.5%-10.7%-32.5%-22.2%-1.8%-1.9%5.8%14.5%8.4%10.1%
ROIC—-14.0%-21.6%-38.1%-21.0%1.8%-2.6%4.9%9.4%8.6%11.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Inogen stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 38% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Inogen pay a dividend?

Not currently.

Is Inogen a good stock to buy?

We do not give buy or sell advice. Inogen scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.